الفهرس Only 14 pages are availabe for public view
 |  | from | 184 |  |  |
| | | from | 184 | | |
Abstract
The association of bronchial asthma with the release of inflammatory mediators, through a mechanism that involves the immune system is a subject of study every day. The role of eosinophil cationic protein (ECP) in allergic inflammatory reaction has been documented in experimental and clinical studies, but its clinical usefulness is still under discussion. The role of specific immunotherapy in asthma management is under continuous investigation.
This study was undertaken to assess the serum and local (BAL fluid) eosinophil cationic protein as an inflammatory mediator involved in asthma pathogenesis and as a prognostic and diagnostic marker of asthma severity and to find any special reference to immunotherapy in asthma management implicating possible impact of immunotherapy on it (ECP).
Thirty extrinsic atopic asthmatic patients and ten apparently healthy persons as a control subjects were included in this study.
All patients and control subjects were subjected to the following pre treatment measures:
1- Thorough medical history stressing on: - Symptoms frequency score.
- Medication score.
2- Clinical examination compnsmg both general and local chest examination.
3- Urine and stool analyses. 4- Skin prick test.
5- Plain chest x-ray postero-anterior and lateral views.